On February 26, 2026, Nektar Therapeutics (Nasdaq: NKTR) revealed plans to disclose its financial performance for Q4 and the year concluding December 31, 2025, on March 12, 2026, following the closure of U.S. financial markets. Howard Robin, the President and Chief Executive Officer, will likely provide insights during this announcement.